Evolving therapeutics in colorectal cancer peritoneal metastases.

Colorectal cancer peritoneal metastases (CRC-PM) are highly aggressive and present distinct therapeutic challenges. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have emerged as potential therapeutic approaches, but their roles remain controversial following recent clinical trials. This review summarizes the evolving landscape of CRC-PM management, including diagnostic challenges, conflicting views of CRS and HIPEC, systemic therapies and new treatment approaches, overview of recent and ongoing landmark clinical trials, and discussion of variations in societal and global guideline recommendations.